Jnana Therapeutics Announces Dosing of First Participant in

JNT-517 is a Potential First-in-Class Oral Treatment for PKU; Phase 1b Study Follows Positive Clinical Proof of Mechanism Data in Healthy Individuals

Related Keywords

Australia , United States , Israel , Oregon , Boston , Massachusetts , Jerusalem , Israel General , Josh Rappaport , Caryo Harding , John Throup , George Vratsanos , Bain Capital Life Sciences , Drug Administration , Linkedin , Twitter , Head Of Development At Jnana Therapeutics , Potential First In Class Oral Treatment , Study Follows Positive Clinical Proof , Mechanism Data , Oral Presentation , Study Results , Inborn Errors , Annual Symposium , Senior Vice President , Upcoming Presentation , Medical Genetics , Oregon Health , Science University School , Healthy Volunteers , Pediatric Disease Designation , Polaris Partners , Versant Ventures , Avalon Ventures , Pfizer Ventures , Relations Josh Rappaport Stern , Oregon News ,